Work

Considering Race and the Potential for ERG Expression as a Biomarker for Prostate Cancer

Year: 2014

Type: article

Abstract: oncogene homolog) is estimated to occur at a rate of 40-50% in prostate cancer. Early evidence suggests that ERG overexpression may be associated with disease progression, and the utilization of ERG levels as a biomarker for prostate cancer is being strongly considered. However, the evidence is incomplete because it relies on studies that primarily focused on men of European ancestry, giving little consideration to African-American men even though African-American men bear a greater disease burden in the form of significantly greater incidence and worse outcomes. In this perspective article we bring to light the issue that the potential use of ERG expression as a biomarker is yet to be solidly established and may have limited utility or varied applicably for African-American men as compared with European-American men.

Source: Personalized Medicine

DOI: 10.2217/pme.14.26

Authors: Isaac J Powell, Gregory Dyson, Sreenivasa R Chinni, Aliccia Bollig-Fischer

Institutions: Wayne State University, The Barbara Ann Karmanos Cancer Institute

Language: English

Topic: Prostate Cancer Treatment and Research

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDGs: Good health and well-being, Reduced inequalities

Open Access status: green

Funders: National Institutes of Health, National Cancer Institute